JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Efficacy of intralesional acyclovir versus quadrivalent human papillomavirus vaccine for treatment of recalcitrant cutaneous warts: a clinical trial

  • 0Faculty of Medicine, Damietta University, Damietta, Egypt.
Archives of Dermatological Research +

|

March 8, 2025

|

March 8, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

The quadrivalent human papillomavirus (HPV) vaccine showed superior efficacy in clearing recalcitrant warts compared to acyclovir. Both treatments were promising, but the HPV vaccine demonstrated better results with manageable side effects.

Area Of Science

  • Dermatology
  • Virology
  • Immunology

Background

  • Warts are skin infections caused by the human papillomavirus (HPV).
  • Current treatments for recalcitrant warts are limited, prompting research into novel therapeutic options.
  • Immunotherapy using HPV vaccines has shown potential for treating warts.

Purpose Of The Study

  • To compare the efficacy and safety of intralesional acyclovir versus quadrivalent HPV vaccine for recalcitrant cutaneous warts.
  • To evaluate the treatment outcomes and recurrence rates for each therapeutic approach.

Main Methods

  • A randomized controlled trial involving 60 patients with recalcitrant warts.
  • Patients were divided into three groups: intralesional acyclovir, intralesional quadrivalent HPV vaccine, or intralesional normal saline (control).
  • Outcomes were assessed monthly for 3 months post-treatment, monitoring for complete clearance and recurrence.

Main Results

  • Complete wart clearance was achieved in 40% of patients receiving acyclovir and 80% receiving the quadrivalent HPV vaccine.
  • No response was observed in the control group.
  • The quadrivalent HPV vaccine group showed statistically significant superiority over the acyclovir group in terms of efficacy.

Conclusions

  • Intralesional acyclovir and quadrivalent HPV vaccine are promising treatments for recalcitrant warts.
  • The quadrivalent HPV vaccine demonstrated superior efficacy compared to acyclovir.
  • Both treatments were generally well-tolerated, with varying side effect profiles.

Keywords: